# Real time fine needle assessment of architectural heterogeneity in prostate cancer

> **NIH NIH R37** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $449,106

## Abstract

ABSTRACT (from the parent grant application)
During the past two decades, prostate cancer (PCa) has become the most commonly diagnosed cancer and
ranks as the second leading cause of cancer deaths for American men. Prostate biopsy is the standard
procedure for evaluating the presence and aggressiveness of PCa. Guided by transrectal ultrasound (TRUS)
and preprocedure magnetic resonance imaging (MRI), small pieces of tissues are removed from the prostate.
The architectural heterogeneities are assigned a Gleason score as a quantitative description of the
aggressiveness. However, TRUS has low sensitivity to PCa. MRI has limited availability, and a spatial mismatch
can occur when co-registering the preprocedure MRI with the real-time TRUS. Therefore, standard TRUS-guided
biopsy, either with or without additional MRI, suffers from missing or under-sampling clinically significant tumors,
leading to under-grading of PCa. At-risk patients with rising blood-based biomarkers undergo repeated and
saturated biopsies, causing extra diagnostic costs and time as well as anxiety and pain.
We propose to solve this long-standing technical gap in PCa diagnosis by introducing a needle photoacoustic
(PA) probe for online guidance of TRUS biopsy. As validated in our preliminary studies on both animal models
and human subjects, quantitative multispectral PA signal analysis possesses the unique capability of objectively
characterizing the architectural heterogeneities in prostate tissues and grading of PCa in vivo. Our needle PA
probe has an all-optical design that allows a small probe dimension to avoid causing additional invasiveness to
the current biopsy procedure. Taking advantage of the optical penetration, the needle PA probe can assess the
histopathological and molecular information in a tissue volume much larger than that of a standard biopsy core.
Hence, PA pre-biopsy measurements, performed together with the TRUS needle biopsy, can provide highly
valuable diagnostic information covering the whole prostate. Core extractions can then be focused within the
suspicious cancerous region(s). The central hypothesis of this research is that a fine needle probe-based PA
prostate pre-biopsy can guide prostate biopsy, improve the core yield, and decrease false negative rates. The
objective of this study is to validate the correlation between the PA measurements and the PCa grading through
an observational human subjects study. The specific aims include investigating the performance of the needle
PA probe in accessing PCa using 1) biopsy tissue cores; 2) ex vivo human prostate samples procured through
prostatectomy, and 3) in vivo human subjects. We will leverage the research team's extensive expertise in the
clinical practice of PCa diagnosis and pathology as well as PA technology. The proposed prebiopsy procedure
is designed within the framework of current clinical practice and is therefore highly translational. The knowledge
gained in this study will prepare us to conduc...

## Key facts

- **NIH application ID:** 10656917
- **Project number:** 4R37CA222829-06
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Guan Xu
- **Activity code:** R37 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $449,106
- **Award type:** 4N
- **Project period:** 2019-01-18 → 2025-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10656917

## Citation

> US National Institutes of Health, RePORTER application 10656917, Real time fine needle assessment of architectural heterogeneity in prostate cancer (4R37CA222829-06). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/10656917. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*